By Fineline Cube Oricell Therapeutics Co., Ltd., a clinical-stage Chinese biotech developing next-generation CAR-T therapies, announced it has raised over USD 110 million in a pre-IPO financing round. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund, with additional participation from an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.
Funding & Strategic Allocation
| Use of Proceeds | Focus Area |
|---|---|
| Clinical Development | Pivotal trials for lead candidate Ori-C101 |
| Global Expansion | Regulatory filings and international trial sites |
| Technology Platform | Scaling multi-mechanism CAR-T R&D (secreted, rapid-manufacture, in vivo) |
| Capital Markets Prep | IPO readiness and governance infrastructure |
Lead Asset: Ori-C101 – A Potential Global First for HCC
- Therapy Type: Autologous CAR-T cell therapy
- Target: GPC3 (glypican-3), highly expressed in hepatocellular carcinoma (HCC)
- Indication: Advanced hepatocellular carcinoma (HCC) — the most common form of primary liver cancer
- Development Stage: Completed investigator-initiated trials (IITs); advancing to pivotal registrational studies
- Differentiation: On track to become the world’s first approved CAR-T therapy for HCC, addressing a major unmet need in oncology
Early clinical data from IITs demonstrated encouraging tumor response and manageable safety, supporting accelerated development under China’s breakthrough therapy pathways.
Platform & Pipeline Depth
Beyond Ori-C101, Oricell has built a full-stack CAR-T technology platform capable of generating:
- Multi-target CAR-Ts for solid tumors
- Secreted cytokine-enhanced constructs to modulate the tumor microenvironment
- Rapid-manufacturing processes (under 7 days) to improve accessibility
- In vivo CAR-T programs leveraging novel delivery vectors
This pipeline positions Oricell at the forefront of solid-tumor CAR-T innovation, a field historically dominated by hematologic indications.
Investor Confidence & Market Context
The oversubscribed round reflects strong institutional appetite for China-based cell therapy innovators with global potential. With over 400,000 new HCC cases annually in China alone and limited effective systemic options for advanced disease, a successful CAR-T approval could command significant market share and premium pricing.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical timelines, regulatory outcomes, and commercial potential. Actual results may differ due to scientific, regulatory, and market risks.-Fineline Info & Tech